ABOUT US

Our vision is to discover, develop and commercialize antibody-based solutions to address the current COVID-19 pandemic, as well as potential future viral diseases with pandemic potential.

ABOUT US

Our vision is to discover, develop and commercialize antibody-based solutions to address the current COVID-19 pandemic, as well as potential future viral diseases with pandemic potential.

At Adagio, our goal is to develop and commercialize differentiated antibody-based solutions with broadly neutralizing activity for the treatment and prevention of diseases caused by SARS CoV-2, its variants and additional SARS-like viruses with pandemic potential. To enable this, our discovery efforts are focused on broadly neutralizing antibodies that target conserved epitopes across multiple members of the coronavirus family.

We also plan to leverage our robust antibody discovery and development capabilities to develop therapeutic or preventative options for other respiratory viral infections, such as seasonal and pandemic influenza.

We were founded in June 2020 to develop a portfolio of anti-coronavirus antibodies discovered by Adimab for both the treatment and prevention of COVID-19 and future coronavirus outbreaks. Our founding scientists discovered ADG20, our lead product candidate, while working at Adimab, an industry leader in translating target hypotheses into therapeutically relevant antibodies. The Adimab platform has been used in more than 385 antibody discovery and optimization programs, more than 40 of which have advanced into clinical trials, including five programs in pivotal clinical trials.

Management Team

Tillman Gerngross, Ph.D.

Tillman Gerngross, Ph.D.

Co-Founder & CEO

Becky Dabora, Ph.D.

Becky Dabora, Ph.D.

Chief Technology & Manufacturing Officer

Lynn Connolly, M.D., Ph.D.

Lynn Connolly, M.D., Ph.D.

Chief Medical Officer

Jane Pritchett Henderson

Jane Pritchett Henderson

Chief Financial Officer

David Hering, M.B.A

David Hering, M.B.A

Chief Operating Officer

Ellie Hershberger, Pharm.D.

Ellie Hershberger, Pharm.D.

Chief Development Officer

Eric Kimble, M.B.A.

Eric Kimble, M.B.A.

Chief Commercial Officer

Laura Walker, Ph.D.

Laura Walker, Ph.D.

Co-Founder & Chief Scientific Officer

Board of Directors

René Russo, Pharm.D.

Co-Founder & Chair of the Board, Adagio
Chief Executive Officer, Xilio Therapeutics

Tillman Gerngross, Ph.D.

Co-Founder & CEO of Adagio and
Adimab, LLC

Tom Heyman

Former President, Johnson & Johnson Development Corporation (JJDC)

Howard Mayer, M.D.

Executive Vice President, Head of Research and Development, Ipsen Pharmaceuticals

Terry McGuire

Partner, Polaris Partners

Ajay Royan

Partner, Mithril Capital

Anand Shah, M.D.

Former Deputy Commissioner for Medical and Scientific Affairs, FDA

Michael Wyzga

President, MSW Consulting, Inc.